Hill 2015.
Methods | Phase II open‐label, randomised study |
Participants | People with KRAS exon 2 WT mCRC progressing on/after oxaliplatin‐containing chemotherapy |
Interventions | FOLFIRI plus duligotuzumab (an antibody directed against EGFR and HER3) vs FOLFIRI plus cetuximab |
Outcomes | Primary endpoint: efficacy. Secondary endpoints: safety and tolerability |
Notes |